LAVA Therapeutics NV at SVB Securities Global Biopharma Conference (Virtual) Transcript
Good afternoon. Good morning, everyone. My name is Daina Graybosch. I am the analyst here at SVB Securities that covers immuno-oncology companies, and I'm pleased to welcome for a presentation and fireside chat the management team from LAVA. And they're going to start with presentation and then we'll get into Q&A. If you'd like me to pose a question to the management team, there's a question box beneath our faces. Go ahead and type it there. And I will try to weave it in. So that, I'll turn it over to Steve to get us started.
Thank you, Daina. And thank you, SVB Securities, for the invitation. And thank you all for those listening online.
My name is Steve Hurly. I'm the CEO of LAVA Therapeutics. It's my pleasure today to introduce you to the company and technology and walk you through some recent clinical data that we have. As a reminder, here's our forward-looking statement. Please review before making any investment decisions.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |